Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Publication
Article
Pharmaceutical TechnologyThe Real Message Behind Commercial mRNA Products, April 2023 eBook
Volume 2023 eBook
Issue 3
Pages: 12–17
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
Shuo - Stock.adobe.com
Nucleic acid-based therapeutics have been stepping up into the spotlight following the deployment of messenger RNA (mRNA) COVID-19 vaccines in 2021 and the rise in clinical development programs for gene therapies. These areas of development may just be the surface of the types of therapeutic applications where nucleic acid-based therapeutics can come into play. Tackling the development challenges of these therapeutics can potentially benefit more expansive areas of unmet medical need, particularly in difficult-to-treat patient populations.
Read this article in Pharmaceutical Technology’s The Real Message Behind Commercial mRNA Products eBook
About the author
Feliza Mirasol is science editor for Pharmaceutical Technology.
Article details
Pharmaceutical Technology
eBook: The Real Message Behind Commercial mRNA Products
April 2023
Pages: 12–17
Citation
When referring to this article, please cite it as Mirasol, F. Nucleic Acid-based Therapeutics Are Stepping into the Spotlight. Pharmaceutical Technology's The Real Message Behind Commercial mRNA Products eBook (April 2023).
Articles in this issue
Stability in mRNA-LNP Formulations
Nucleic Acid-based Therapeutics Are Stepping into the Spotlight
Learning to Think at Lightspeed
Managing mRNA Instability
The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products
The Marriage of RNA and Mass Spectrometry
Delivering on the Potential of mRNA Therapeutics
The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
